Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 17/20 | 0.63 |
| ▸ | ERBB2 known ✓ | P04626 | 7/20 | 0.59 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.57 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.57 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.57 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.57 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.57 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.57 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.57 |
| ▸ | TEC known ✓ | P42680 | 1/20 | 0.57 |
| ▸ | TXK known ✓ | P42681 | 1/20 | 0.57 |
| ▸ | CSNK1E known ✓ | P49674 | 1/20 | 0.57 |
| ▸ | BMX known ✓ | P51813 | 1/20 | 0.57 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.57 |
| ▸ | BTK known ✓ | Q06187 | 1/20 | 0.57 |
| ▸ | ITK known ✓ | Q08881 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 3/20 | 0.57 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.57 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18138479 | 0.94 | EGFR (0.63) | EGFRERBB2SRCKITERBB3 | |
| SCHEMBL18138468 | 0.94 | EGFR (0.68) | EGFRERBB2SRCKITERBB3 | |
| Sulfuric Acid SCHEMBL18138481 | 0.94 | EGFR (0.68) | EGFRERBB2SRCKITERBB3 | |
| SCHEMBL18138482 | 0.93 | EGFR (0.66) | EGFRERBB2SRCKITERBB3 | |
| SCHEMBL16809094 | 0.93 | EGFR (0.71) | EGFRERBB2SRCKITERBB3 | |
| Hydrochloric Acid SCHEMBL18138465 | 0.92 | EGFR (0.70) | EGFRERBB2SRCKITERBB3 | |
| Bromide SCHEMBL18138475 | 0.92 | EGFR (0.70) | EGFRERBB2SRCKITERBB3 | |
| Acetic Acid SCHEMBL20496158 | 0.91 | EGFR (0.69) | EGFRERBB2SRCKITERBB3 | |
| Oxalic Acid SCHEMBL20496149 | 0.91 | EGFR (0.69) | EGFRERBB2SRCKITERBB3 | |
| Phosphoric Acid SCHEMBL18138470 | 0.91 | EGFR (0.69) | EGFRERBB2SRCKITERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081563-B1 | QUINAZOLINE DERIVATIVE AND SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2018-09-19 | — | — | EP | claimed |
| US-9840494-B2 | Quinazoline derivative | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-12-12 | — | — | US | claimed |
| US-20160311796-A1 | QUINAZOLINE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD | 2016-10-27 | — | — | US | claimed |
| EP-3081563-A1 | QUINAZOLINE DERIVATIVE | Tianjin Hemay Pharmaceutical Sci-tech Co. Ltd. (CN) | 2016-10-19 | — | — | EP | claimed |
| EP-3081563-B1 | QUINAZOLINE DERIVATIVE AND SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-9840494-B2 | Quinazoline derivative | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-20160311796-A1 | QUINAZOLINE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD | 2016-10-27 | — | — | US | disclosed |
| EP-3081563-A1 | QUINAZOLINE DERIVATIVE | Tianjin Hemay Pharmaceutical Sci-tech Co. Ltd. (CN) | 2016-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311796-A1 | QUINAZOLINE DERIVATIVE | NQO2, ABL1, HDAC6 | EGFR 3950/4885ERBB2 2520/4885KIT 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.